TY - JOUR AU - Chen, Dan AU - Wang, Juan AU - Fu, Jianglin PY - 2020/05/05 Y2 - 2024/03/29 TI - Serum Chemerin Predicts the Prognosis of Patients With Dilated Cardiomyopathy JF - The Heart Surgery Forum JA - HSF VL - 23 IS - 3 SE - DO - 10.1532/hsf.2885 UR - https://journal.hsforum.com/index.php/HSF/article/view/2885 SP - E276-E280 AB - <p class="p1"><span class="s1"><strong>Background: </strong>Chemerin is a newly discovered adipokine, which has been reported to be associated with the presence of dilated cardiomyopathy (DCM). The present study aims to evaluate the prognostic value of serum chemerin in patients with DCM.</span></p><p class="p1"><span class="s1"><strong>Methods:</strong> A total of 214 patients with DCM was recruited and divided into 4 groups, according to quartiles of chemerin levels. Kaplan–Meier analysis was conducted to compare the survival rates among patients with different levels of chemerin, using the log-rank test. Multivariate Cox regression analysis was performed to assess the association of serum chemerin levels and occurrence of major adverse cardiac events (MACEs), including cardiac mortality, stroke and myocardial infarction.</span></p><p class="p1"><span class="s1"><strong>Results: </strong>The Kaplan-Meier survival analysis indicated that patients with higher concentration of chemerin had shorter event-free survivals for MACEs (<em>P</em> &lt; .01). Cox regression analysis showed that chemerin was a significant predictor of MACEs (Quartile 3 versus Quartile 1: HR=1.79, 95% CI: 1.31-2.79; Quartile 4 versus Quartile 1: HR=2.87, 95% CI: 1.79-4.25) and all-cause death (Quartile 3 versus Quartile 1: HR=1.56, 95% CI: 1.20-2.42; Quartile 4 versus Quartile 1: HR=2.28, 95% CI: 1.52-3.96) after adjusting for potential risk factors.</span></p><p class="p1"><span class="s1"><strong>Conclusion:</strong> Serum chemerin should be a potential prognostic indicator in patients with DCM.</span></p> ER -